Association of Postdischarge Spending and Performance on New Episode-Based Spending Measure

Spending on New Drug Development

This paper replicates DiMasi et al (2003, 2004) estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $25m per year, with $18m per year on drugs in Phase 1, $33m on drugs in Phase 2 and $19m per year on drugs in Phase 3 of the human clinical trials. The paper’s estimated expenditur...

A New Focus on Prescription Drug Spending.

Radio’s Impact on New Deal Spending

Mass media carry political information to the voter. This makes voters using mass media more likely to respond to campaign promises and to hold politicians accountable for cuts that hurt them. As a consequence, politicians should target voters using mass media. These ideas are developed in a voting model which is then used as a basis for empirical investigation. To isolate the e¤ects of mass me...

Medical Out - of - Pocket Spending Among the Uninsured : Differential Spending & the Supplemental Poverty Measure ∗

This paper refines the treatment of Medical Out-of-Pocket (MOOP) spending among the uninsured in measuring poverty, and investigates its net effect on the Supplemental Poverty Measure (SPM). Unlike previous work, this research accounts for insurance coverage type in estimating counterfactual distributions of non-premium MOOP spending for the uninsured using predictive mean matching models. Addi...

Performance growth and opportunistic marketing spending

Article history: First received on November 5, 2014 and was under review for 51⁄2 months Available online xxxx Area Editor: Sunil Gupta Marketing executives are under pressure to produce revenue and profit growth for their brands. In most cases that involve requesting gradually higher marketing budgets, which is expensive, especially considering the known diminishing return effects of marketing...